HK Stock Market Move | TYK MEDICINES-B(02410) surged over 40% in early trading. TY-9591 key Phase II clinical trial investigator data meets research expectations.

TYK MEDICINES-B (02410) rose more than 40% in the morning session, and as of press time, it had risen by 36.93% to 41.9 Hong Kong dollars, with a turnover of 3.3 million Hong Kong dollars. In terms of news, on March 9th, TYK MEDICINES-B announced that the company's independently developed TY-9591 (trade name: Kadasha) has shown statistically significant and clinically significant improvements compared to osimertinib (trade name: Tarissa) in a phase II clinical trial as a first-line treatment for brain metastases in EGFR-mutated lung cancer, according to data from researchers. The primary study endpoint, intracranial objective response rate (iORR), achieved the expected goals. TY-9591 showed statistically significant and clinically significant improvements compared to osimertinib, with significant statistical differences in both the overall population and different subgroups (including genetic typing, number of intracranial lesions, ECOG score, etc.). The company plans to submit a New Drug Application (NDA) for market approval to the National Medical Products Administration's Center for Drug Evaluation (CDE) in the near future.